<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Does Semaglutide Cause Muscle Loss? What the 2025 Research Actually Shows — Élan Clinic</title>
  <meta name="description" content="25–39% of weight lost on semaglutide is lean tissue, not fat. Here's what the 2025 research actually shows about muscle loss on Ozempic — and what you can do about it." />
  <link rel="canonical" href="https://elan.clinic/blog/muscle-loss-on-semaglutide.html" />
  <link rel="icon" type="image/svg+xml" href="/favicon.svg" />

  <!-- Open Graph -->
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://elan.clinic/blog/muscle-loss-on-semaglutide.html" />
  <meta property="og:title" content="Does Semaglutide Cause Muscle Loss? What the 2025 Research Actually Shows" />
  <meta property="og:description" content="25–39% of weight lost on semaglutide is lean tissue, not fat. Here's what the research shows — and what you can do about it." />
  <meta property="og:locale" content="en_GB" />
  <meta property="article:published_time" content="2026-02-28" />
  <meta property="article:author" content="Dr. Ingmar Lindström" />

  <!-- Schema.org MedicalWebPage Structured Data -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "Does Semaglutide Cause Muscle Loss? What the 2025 Research Actually Shows",
    "headline": "Does Semaglutide Cause Muscle Loss? What the 2025 Research Actually Shows",
    "url": "https://elan.clinic/blog/muscle-loss-on-semaglutide.html",
    "datePublished": "2026-02-28",
    "inLanguage": "en",
    "description": "25–39% of weight lost on semaglutide is lean tissue, not fat. Here's what the 2025 research actually shows about muscle loss on Ozempic — and what you can do about it.",
    "about": {
      "@type": "MedicalCondition",
      "name": "Sarcopenia"
    },
    "medicalAudience": {
      "@type": "MedicalAudience",
      "audienceType": "Patient"
    },
    "author": {
      "@type": "Person",
      "name": "Dr. Ingmar Lindström",
      "jobTitle": "Physician",
      "worksFor": {
        "@type": "MedicalClinic",
        "name": "Élan Clinic",
        "url": "https://elan.clinic"
      }
    },
    "publisher": {
      "@type": "MedicalClinic",
      "name": "Élan Clinic",
      "url": "https://elan.clinic",
      "logo": "https://elan.clinic/favicon.svg",
      "telephone": "+37252999399",
      "address": {
        "@type": "PostalAddress",
        "streetAddress": "Sepapaja 12/1",
        "addressLocality": "Tallinn",
        "postalCode": "11415",
        "addressCountry": "EE"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://elan.clinic/blog/muscle-loss-on-semaglutide.html"
    },
    "citation": [
      {
        "@type": "ScholarlyArticle",
        "name": "GLP-1 receptor agonists cause skeletal muscle wasting: evidence-based strategies to attenuate it",
        "isPartOf": { "@type": "Periodical", "name": "ScienceDirect" },
        "datePublished": "2025"
      },
      {
        "@type": "ScholarlyArticle",
        "name": "GLP-1 receptor activation affects muscle fibre function independent of caloric deficit",
        "isPartOf": { "@type": "Periodical", "name": "University of Utah Health Research" },
        "datePublished": "2025"
      }
    ]
  }
  </script>

  <!-- Google Fonts -->
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500&family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet" />

  <style>
    /* ─── Reset & Base ─────────────────────────────────────────────── */
    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }

    html { scroll-behavior: smooth; font-size: 16px; }

    body {
      font-family: 'Inter', sans-serif;
      background-color: #0D1B2A;
      color: rgba(232, 228, 222, 0.55);
      line-height: 1.7;
      -webkit-font-smoothing: antialiased;
    }

    h1, h2, h3, h4 {
      font-family: 'Playfair Display', serif;
      color: #E8E4DE;
      line-height: 1.2;
      font-weight: 500;
    }

    a { color: #C5A55A; text-decoration: none; }
    a:hover { text-decoration: underline; }

    /* ─── Layout ───────────────────────────────────────────────────── */
    .container {
      width: 100%;
      max-width: 1200px;
      margin: 0 auto;
      padding: 0 24px;
    }

    /* ─── Gold Utilities ───────────────────────────────────────────── */
    .label {
      display: inline-block;
      font-family: 'Inter', sans-serif;
      font-size: 0.7rem;
      font-weight: 600;
      letter-spacing: 0.18em;
      text-transform: uppercase;
      color: #C5A55A;
      margin-bottom: 20px;
    }

    .gold-line {
      width: 48px;
      height: 2px;
      background: #C5A55A;
      margin: 28px 0;
    }

    /* ─── Nav ──────────────────────────────────────────────────────── */
    .nav {
      position: fixed;
      top: 0; left: 0; right: 0;
      z-index: 100;
      padding: 20px 24px;
      display: flex;
      align-items: center;
      justify-content: space-between;
      background: rgba(13, 27, 42, 0.92);
      backdrop-filter: blur(12px);
      border-bottom: 1px solid rgba(197, 165, 90, 0.12);
    }

    .nav__logo {
      font-family: 'Playfair Display', serif;
      font-size: 1.25rem;
      color: #E8E4DE;
      letter-spacing: 0.06em;
      text-decoration: none;
    }

    .nav__logo span { color: #C5A55A; }

    .nav__links {
      display: flex;
      align-items: center;
      gap: 32px;
      list-style: none;
    }

    .nav__links a {
      font-size: 0.78rem;
      font-weight: 500;
      letter-spacing: 0.1em;
      text-transform: uppercase;
      color: rgba(232, 228, 222, 0.65);
      text-decoration: none;
      transition: color 0.2s;
    }

    .nav__links a:hover,
    .nav__links a.active { color: #C5A55A; }

    /* ─── Breadcrumb ───────────────────────────────────────────────── */
    .breadcrumb {
      padding: 120px 0 0;
      background-color: #0D1B2A;
    }

    .breadcrumb__inner {
      display: flex;
      align-items: center;
      gap: 8px;
      flex-wrap: wrap;
    }

    .breadcrumb__item {
      font-size: 0.75rem;
      font-weight: 500;
      letter-spacing: 0.08em;
      color: rgba(232, 228, 222, 0.4);
      text-transform: uppercase;
    }

    .breadcrumb__item a {
      color: rgba(232, 228, 222, 0.4);
      text-decoration: none;
      transition: color 0.2s;
    }

    .breadcrumb__item a:hover {
      color: #C5A55A;
      text-decoration: none;
    }

    .breadcrumb__sep {
      font-size: 0.7rem;
      color: rgba(197, 165, 90, 0.4);
    }

    .breadcrumb__item--current {
      color: #C5A55A;
    }

    /* ─── Article Header ───────────────────────────────────────────── */
    .article-header {
      padding: 48px 0 64px;
      background-color: #0D1B2A;
      position: relative;
      overflow: hidden;
    }

    .article-header::before {
      content: '';
      position: absolute;
      top: -100px; right: -150px;
      width: 500px; height: 500px;
      background: radial-gradient(circle, rgba(197,165,90,0.05) 0%, transparent 70%);
      pointer-events: none;
    }

    .article-header__content { max-width: 780px; }

    .article-header h1 {
      font-size: clamp(2rem, 4.5vw, 3.2rem);
      line-height: 1.15;
      margin-bottom: 28px;
    }

    .article-meta {
      display: flex;
      align-items: center;
      flex-wrap: wrap;
      gap: 24px;
      padding-top: 24px;
      border-top: 1px solid rgba(197, 165, 90, 0.15);
    }

    .article-meta__item {
      display: flex;
      align-items: center;
      gap: 8px;
      font-size: 0.8rem;
      color: rgba(232, 228, 222, 0.5);
    }

    .article-meta__item strong {
      color: rgba(232, 228, 222, 0.75);
      font-weight: 500;
    }

    .article-meta__dot {
      width: 3px; height: 3px;
      border-radius: 50%;
      background: rgba(197, 165, 90, 0.4);
    }

    /* ─── Article Body ─────────────────────────────────────────────── */
    .article-body {
      padding: 0 0 100px;
      background-color: #0D1B2A;
    }

    .article-body__inner { max-width: 780px; }

    .article-body p {
      font-size: 1.05rem;
      color: rgba(232, 228, 222, 0.72);
      line-height: 1.85;
      margin-bottom: 28px;
    }

    .article-body h2 {
      font-size: clamp(1.5rem, 2.5vw, 2rem);
      margin: 56px 0 20px;
      color: #E8E4DE;
    }

    .article-body h3 {
      font-size: clamp(1.1rem, 2vw, 1.35rem);
      margin: 40px 0 16px;
      color: #E8E4DE;
    }

    .article-body strong {
      color: rgba(232, 228, 222, 0.9);
      font-weight: 600;
    }

    .article-body em {
      color: rgba(232, 228, 222, 0.65);
      font-style: italic;
    }

    .article-body hr {
      border: none;
      height: 1px;
      background: rgba(197, 165, 90, 0.15);
      margin: 48px 0;
    }

    /* ─── Pull Quote ───────────────────────────────────────────────── */
    .pull-quote {
      border-left: 3px solid #C5A55A;
      padding: 20px 32px;
      margin: 40px 0;
      background: rgba(197, 165, 90, 0.04);
    }

    .pull-quote p {
      font-family: 'Playfair Display', serif;
      font-size: 1.2rem !important;
      font-style: italic;
      color: rgba(232, 228, 222, 0.82) !important;
      line-height: 1.6 !important;
      margin: 0 !important;
    }

    /* ─── Key Stat ─────────────────────────────────────────────────── */
    .key-stat {
      background: #111D2E;
      border: 1px solid rgba(197, 165, 90, 0.18);
      padding: 32px 36px;
      margin: 40px 0;
    }

    .key-stat__number {
      font-family: 'Playfair Display', serif;
      font-size: 3rem;
      color: #C5A55A;
      line-height: 1;
      margin-bottom: 8px;
    }

    .key-stat__label {
      font-size: 0.88rem;
      color: rgba(232, 228, 222, 0.6);
      line-height: 1.5;
    }

    /* ─── Article Sources ──────────────────────────────────────────── */
    .article-sources {
      margin-top: 60px;
      padding-top: 32px;
      border-top: 1px solid rgba(197, 165, 90, 0.12);
    }

    .article-sources p {
      font-size: 0.82rem !important;
      color: rgba(232, 228, 222, 0.38) !important;
      line-height: 1.6 !important;
      margin-bottom: 8px !important;
    }

    .article-sources .sources-label {
      font-size: 0.7rem;
      font-weight: 600;
      letter-spacing: 0.15em;
      text-transform: uppercase;
      color: #C5A55A;
      margin-bottom: 16px;
      display: block;
    }

    /* ─── Back Link ────────────────────────────────────────────────── */
    .back-link {
      display: inline-flex;
      align-items: center;
      gap: 8px;
      font-size: 0.78rem;
      font-weight: 600;
      letter-spacing: 0.1em;
      text-transform: uppercase;
      color: rgba(232, 228, 222, 0.5);
      text-decoration: none;
      transition: color 0.2s, gap 0.2s;
      margin-bottom: 60px;
    }

    .back-link:hover {
      color: #C5A55A;
      gap: 12px;
      text-decoration: none;
    }

    /* ─── Footer CTA ───────────────────────────────────────────────── */
    .footer-cta {
      background-color: #111D2E;
      border-top: 1px solid rgba(197, 165, 90, 0.12);
      text-align: center;
      padding: 100px 24px;
    }

    .footer-cta h2 {
      max-width: 620px;
      margin: 0 auto 24px;
      font-size: clamp(1.6rem, 3vw, 2.2rem);
    }

    .footer-cta__sub {
      max-width: 480px;
      margin: 0 auto 40px;
      font-size: 0.95rem;
    }

    /* ─── Button ───────────────────────────────────────────────────── */
    .btn {
      display: inline-block;
      padding: 16px 36px;
      font-family: 'Inter', sans-serif;
      font-size: 0.85rem;
      font-weight: 600;
      letter-spacing: 0.1em;
      text-transform: uppercase;
      border: 1.5px solid #C5A55A;
      color: #C5A55A;
      background: transparent;
      cursor: pointer;
      transition: background 0.2s, color 0.2s;
      text-decoration: none;
    }

    .btn:hover {
      background: #C5A55A;
      color: #0D1B2A;
      text-decoration: none;
    }

    .btn--filled {
      background: #C5A55A;
      color: #0D1B2A;
    }

    .btn--filled:hover {
      background: #d4b56a;
      color: #0D1B2A;
    }

    /* ─── Footer Legal ─────────────────────────────────────────────── */
    .footer-legal {
      background-color: #0D1B2A;
      border-top: 1px solid rgba(197, 165, 90, 0.08);
      padding: 40px 24px;
    }

    .footer-legal__inner {
      max-width: 1200px;
      margin: 0 auto;
      display: flex;
      flex-direction: column;
      gap: 8px;
    }

    .footer-legal p {
      font-size: 0.75rem;
      color: rgba(232, 228, 222, 0.3);
      line-height: 1.6;
    }

    /* ─── Responsive ───────────────────────────────────────────────── */
    @media (max-width: 768px) {
      .nav__links { gap: 16px; }
      .nav__links a { font-size: 0.72rem; }
      .breadcrumb { padding-top: 100px; }
      .article-header { padding: 32px 0 48px; }
      .article-body p { font-size: 0.98rem; }
      .key-stat__number { font-size: 2.4rem; }
      .pull-quote { padding: 16px 20px; }
    }
  </style>
</head>
<body>

  <!-- ─── Navigation ────────────────────────────────────────────── -->
  <nav class="nav">
    <a href="/" class="nav__logo">Élan<span>.</span></a>
    <ul class="nav__links">
      <li><a href="/">Home</a></li>
      <li><a href="/blog.html" class="active">Articles</a></li>
      <li><a href="/faq.html">FAQ</a></li>
      <li style="margin-left:8px;border-left:1px solid rgba(197,165,90,0.25);padding-left:16px;display:flex;gap:12px;"><a href="/et.html" style="font-size:0.7rem;">EST</a> <a href="/ukk.html" style="font-size:0.7rem;">FIN</a> <a href="/voprosy.html" style="font-size:0.7rem;">RUS</a></li>
      <li><a href="/#consultation" class="btn" style="padding: 10px 20px; font-size: 0.72rem;">Book a Consultation</a></li>
    </ul>
  </nav>

  <!-- ─── Breadcrumb ────────────────────────────────────────────── -->
  <div class="breadcrumb">
    <div class="container">
      <nav class="breadcrumb__inner" aria-label="Breadcrumb">
        <span class="breadcrumb__item"><a href="/">Home</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item"><a href="/blog.html">Articles</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item breadcrumb__item--current">Muscle Loss on Semaglutide</span>
      </nav>
    </div>
  </div>

  <!-- ─── Article Header ───────────────────────────────────────── -->
  <header class="article-header">
    <div class="container">
      <div class="article-header__content">
        <span class="label">GLP-1 Medications · Body Composition</span>
        <h1>Does Semaglutide Cause Muscle Loss? What the 2025 Research Actually Shows.</h1>
        <div class="article-meta">
          <div class="article-meta__item">
            <strong>Dr. Ingmar Lindström</strong>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            <time datetime="2026-02-28">February 28, 2026</time>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            8 min read
          </div>
        </div>
      </div>
    </div>
  </header>

  <!-- ─── Article Body ──────────────────────────────────────────── -->
  <main class="article-body">
    <div class="container">
      <div class="article-body__inner">

        <p>
          You've lost weight. The number on the scale is lower than it's been in years. But something feels off — you're weaker than expected, your clothes hang differently than you imagined, and you've seen enough Reddit threads about "Ozempic face" to start wondering what's actually happening beneath the surface.
        </p>

        <p>
          This is a real question. It deserves a real answer — not reassurance, not alarm.
        </p>

        <p>
          Muscle loss on semaglutide is a topic that's finally getting serious scientific attention in 2025. The honest answer is that yes, it's a real phenomenon, it's more significant than early messaging suggested, and — crucially — there is a lot you can do about it. Let me walk you through what the research actually shows.
        </p>

        <hr />

        <h2>What GLP-1s actually do to body composition</h2>

        <h3>How weight loss works on semaglutide — the caloric deficit mechanism</h3>

        <p>
          Semaglutide (the active ingredient in Ozempic and Wegovy) works primarily by mimicking a gut hormone called GLP-1, which suppresses appetite, slows gastric emptying, and enhances satiety signalling in the brain. The result: people eat substantially less without feeling deprived. Clinical trials show average weight losses of 12–15% of body weight over 68 weeks on therapeutic doses.
        </p>

        <p>
          But here's what matters for this conversation: weight loss — <em>any</em> weight loss — achieved through caloric restriction results in a mix of fat and lean tissue loss. The body doesn't selectively burn fat. Semaglutide creates a significant caloric deficit, and that deficit pulls from all available stores.
        </p>

        <h3>The fat-free mass problem</h3>

        <p>
          Multiple body composition studies published in 2024–2025 show that <strong>25–39% of the weight lost on semaglutide is lean tissue</strong> — not fat. That's not a rounding error. On a typical 15kg weight loss, that could represent 4–6kg of lean mass, including muscle.
        </p>

        <div class="key-stat">
          <div class="key-stat__number">25–39%</div>
          <div class="key-stat__label">of weight lost on semaglutide is lean tissue — not fat — according to body composition studies published in 2024–2025.</div>
        </div>

        <p>
          For context: losing 4–6kg of muscle would represent a meaningful setback for any fitness goal and a significant metabolic shift — because muscle tissue is metabolically active. Less muscle means a lower resting metabolic rate, which means your body burns fewer calories at rest. This is one of the mechanisms behind the weight regain pattern: <a href="/blog/ozempic-aftermath-why-weight-comes-back.html">why weight comes back after stopping GLP-1 medication</a>.
        </p>

        <h3>Muscle mass vs. muscle strength — an important distinction</h3>

        <p>
          Here's something the headlines often miss. Research from the University of Utah Health (October 2025) showed that <strong>muscles may get weaker even when the actual reduction in muscle mass is smaller than expected</strong>. In mouse models, GLP-1 receptor activation appeared to affect muscle fibre function directly — independent of the caloric deficit.
        </p>

        <p>
          This may explain why some people report feeling weaker or noticing reduced exercise performance even when their body composition scans don't show dramatic lean mass losses. It's a nuance worth understanding: mass and function are not the same thing.
        </p>

        <hr />

        <h2>Why this matters more at 40+ — the sarcopenia context</h2>

        <h3>Starting point matters</h3>

        <p>
          Age-related muscle loss — sarcopenia — begins around age 35 and accelerates after 50, with natural rates of 1–2% per year if untreated. People over 40 who use semaglutide are often already navigating this baseline decline. Adding medication-associated lean mass loss on top of age-related loss is a compounding problem that deserves clinical attention, not a wave of reassurance.
        </p>

        <h3>The metabolic consequences of reduced lean mass</h3>

        <p>
          Muscle tissue is insulin-sensitive. When you lose lean mass, you reduce the body's capacity to handle glucose efficiently — which is somewhat ironic given that GLP-1 medications are frequently prescribed to people with metabolic concerns including type 2 diabetes or pre-diabetes. Preserving lean mass isn't just about aesthetics or strength. It's directly relevant to metabolic health outcomes.
        </p>

        <h3>"Thinner but weaker" is not a longevity win</h3>

        <p>
          The goal of meaningful weight management isn't a lower number on a scale — it's better health. A ScienceDirect review published in August 2025 was explicit: <em>GLP-1 receptor agonists cause skeletal muscle wasting, and evidence-based strategies exist to attenuate it.</em> That's a significant statement from a peer-reviewed source, and it reframes the conversation from "is this a problem?" to "what do we do about it?"
        </p>

        <h3>The regain problem compounds this</h3>

        <p>
          When people stop GLP-1 medication, the weight that returns is primarily fat — not lean tissue. Sword Health data from 2025 suggests that approximately two-thirds of weight regained after stopping semaglutide is fat mass. If you've already lost muscle during the active treatment phase, you're entering the post-medication period with a worse body composition starting point than when you began. This is one of the more under-discussed risks of GLP-1 therapy without a structured body composition strategy alongside it.
        </p>

        <hr />

        <h2>What the research says about prevention</h2>

        <p>
          This is the part that matters most — because muscle loss on semaglutide is not inevitable.
        </p>

        <h3>Resistance training — the single most evidence-backed intervention</h3>

        <p>
          The evidence here is consistent across multiple randomised controlled trials: <strong>resistance training 2–3 times per week preserves 60–80% more lean mass during caloric restriction</strong> compared to no training. This holds true during GLP-1 therapy specifically.
        </p>

        <div class="pull-quote">
          <p>Resistance training 2–3 times per week preserves 60–80% more lean mass during caloric restriction compared to no training.</p>
        </div>

        <p>
          The key words are <em>resistance</em> and <em>progressive overload</em>. Walking, cycling, swimming — these are all valuable for cardiovascular health, but they don't provide the mechanical stimulus needed to preserve or build muscle tissue. Compound movements — squats, deadlifts, rows, presses — engage large muscle groups and signal the body to maintain lean mass even in a caloric deficit.
        </p>

        <p>
          Practically: 2–3 sessions per week, at a meaningful intensity level, with gradual progression over time. This doesn't require a gym membership or a personal trainer, though both help. The point is consistency and load.
        </p>

        <p>
          <strong>Timing note:</strong> Some people find that resistance training in the days following their semaglutide injection — when appetite suppression is strongest — can be challenging due to low energy. Experimenting with training timing relative to injection day is worth the effort.
        </p>

        <h3>Protein — the 1.6g/kg/day evidence base</h3>

        <p>
          The research on protein and lean mass preservation is among the most robust in sports medicine and obesity research: <strong>protein intake of at least 1.6g per kilogram of body weight per day</strong> is associated with meaningful preservation of lean mass during weight loss.
        </p>

        <p>
          For someone weighing 90kg, that's 144g of protein per day — not an easy target when your appetite is dramatically suppressed by semaglutide. This is where intentional meal planning matters. Prioritising protein at every eating opportunity (even when appetite is low), choosing leucine-rich sources — eggs, fish, chicken, Greek yoghurt, legumes — and considering a protein supplement if dietary intake is consistently falling short are all evidence-supported approaches.
        </p>

        <p>
          The leucine point is specific: leucine is the branched-chain amino acid most directly involved in muscle protein synthesis signalling. Getting adequate leucine at each meal — rather than batching all protein into one meal — appears to matter for muscle preservation.
        </p>

        <h3>Creatine — emerging evidence worth noting</h3>

        <p>
          Creatine monohydrate has decades of evidence for muscle strength and lean mass support during resistance training. More recent research is exploring its relevance during GLP-1 therapy specifically, and while the data isn't yet definitive in this particular context, the safety profile is excellent and the general evidence base is strong. If you're doing resistance training, creatine (3–5g daily) is a reasonable addition. If you're not doing resistance training, it's not a substitute.
        </p>

        <h3>Why cardio alone won't preserve lean mass</h3>

        <p>
          This needs to be said directly, because many people default to cardio when they want to "do more" during a weight loss phase. Cardiovascular exercise is important for heart health, mood, and longevity — but it does not provide the mechanical stimulus that muscles need to be maintained. Running more while eating less, without resistance training, is among the fastest paths to the lean mass losses we're trying to prevent.
        </p>

        <hr />

        <h2>What to do if you've already lost muscle on GLP-1s</h2>

        <h3>You can rebuild</h3>

        <p>
          This is genuinely reassuring: skeletal muscle is responsive to training stimulus at any age, and the evidence shows that muscle lost during weight loss is recoverable. It takes time and consistent effort, but it is not a permanent condition. The body does not forget how to build muscle.
        </p>

        <h3>Body composition testing — the scale is the wrong tool here</h3>

        <p>
          If you're concerned about muscle loss on semaglutide, the scale is not going to tell you what you need to know. A 2kg weight gain could represent fat regain or muscle rebuilding — the number looks the same. Tools like InBody bioelectrical impedance analysis or DEXA scanning can distinguish between fat mass, lean mass, and bone density, giving you actual data to work with.
        </p>

        <p>
          Tracking body composition — not just weight — changes the entire frame of what success looks like. Someone who gains 2kg of muscle while losing 3kg of fat is moving in a profoundly positive direction, even if the scale shows a 1kg drop. Without composition data, you're navigating in the dark.
        </p>

        <h3>Building a protocol around your medication phase</h3>

        <p>The approach should differ depending on where you are in your GLP-1 journey:</p>

        <p>
          <strong>Active treatment phase:</strong> Focus on resistance training + protein targets. Don't rely on hunger to signal when to eat protein — eat on schedule, aiming for 1.6g/kg/day.
        </p>

        <p>
          <strong>Dose stabilisation or plateau phase:</strong> This is often when people can push harder in training as side effects settle. A good window to increase training intensity.
        </p>

        <p>
          <strong>Post-medication phase:</strong> Priority shifts to rebuilding any lost lean mass while managing the biological drive to regain weight. See our article on <a href="/blog/ozempic-aftermath-why-weight-comes-back.html">what actually happens to your weight after stopping GLP-1 medication</a> for the full picture on that transition.
        </p>

        <hr />

        <h2>The physician's take — nuance over narrative</h2>

        <p>
          The "GLP-1 ruins your muscles" headline and the "nothing to worry about" dismissal are both wrong. The evidence in 2025 supports two things simultaneously: legitimate concern about lean mass loss during semaglutide therapy, <em>and</em> effective, evidence-based strategies to prevent most of it.
        </p>

        <p>
          The LA Times ran expert commentary in January 2026 stating: <em>"Concerns regarding muscle loss on semaglutide are valid but require nuance."</em> That's the right framing.
        </p>

        <p>
          The people who do worst are those who lose weight passively — medication only, no structural changes to protein intake or physical activity. The people who do best are those who treat the medication as one tool within a broader strategy that includes strength training and adequate protein.
        </p>

        <p>
          Weight management is an infinite game. Medication can change the rules for a while — but the fundamentals of lean mass preservation remain constant regardless of what you're taking or whether you're taking anything at all.
        </p>

        <p>
          If you want to understand where you actually stand — how much lean mass you have, what your current metabolic picture looks like, and what a structured protocol for your specific situation would involve — a body composition analysis and personalised consultation is the place to start. That's what we do at Élan.
        </p>

        <!-- ─── Sources ─────────────────────────────────────────── -->
        <div class="article-sources">
          <span class="sources-label">Sources</span>
          <p>University of Utah Health. "GLP-1 receptor activation affects muscle fibre function independent of caloric deficit." <em>Research report</em>, October 2025.</p>
          <p>ScienceDirect review: "GLP-1 receptor agonists cause skeletal muscle wasting: evidence-based strategies to attenuate it." <em>ScienceDirect</em>, August 2025.</p>
          <p>Sword Health. Body composition analysis data from GLP-1 discontinuation cohort. 2025.</p>
          <p>LA Times. Expert commentary on semaglutide and muscle loss. January 2026.</p>
        </div>

        <!-- ─── Back Link ──────────────────────────────────────── -->
        <a href="/blog.html" class="back-link">← Back to Articles</a>

      </div>
    </div>
  </main>

  <!-- ─── Footer CTA ────────────────────────────────────────────── -->
  <section class="footer-cta">
    <span class="label">Consultation</span>
    <h2>Know Where You Actually Stand.</h2>
    <p class="footer-cta__sub">
      A body composition analysis and 45-minute consultation to understand your lean mass, metabolic picture, and what a structured protocol for your situation looks like.
    </p>
    <a href="tel:+37252999399" class="btn btn--filled">Call +372 52 99939</a>
  </section>

  <!-- ─── Footer Legal ──────────────────────────────────────────── -->
  <footer class="footer-legal">
    <div class="footer-legal__inner">
      <p>© 2026 Élan Clinic · Elan Clinic OÜ · Reg 17338832 · Medical licence L07470 · Sepapaja 12/1, Tallinn 11415</p>
      <p>This article is for informational purposes only and does not constitute medical advice. Consult your physician before changing any medication or health programme.</p>
    </div>
  </footer>

</body>
</html>
